This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comCRA Life Sciences continues its series on leveraging RADAR, an orphan drug data repository. With rare oncology diseases in the spotlight at ASCO this season,...
Radioligand therapies (RLTs) are poised to transform the oncology treatment paradigm and transition to more mainstream treatment in oncology. Recent commercial...
CRA is a proud sponsor of the conference that aims to increase the prominence of women through professional development, substantive legal discussion, and...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
